Application of ergothioneine and combination of ergothioneine as acrolein inhibitor

Through the combination of ergothionein and its adducting products with γ-aminobutyric acid or disodium 5'-guanylate, the problem of limited application of acrolein inhibitors in food in the prior art is solved, and the problem of intra-administration of acrolein inhibitors is achieved. Effectively inhibit the production and reaction of acrolein at high temperatures, and improve food safety and environmental protection effects.

CN119073569APending Publication Date: 2024-12-06NANJING NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411184662.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing acrolein inhibitors in food are restricted by color, odor and solubility, and the structure is unstable during high-temperature processing, which cannot effectively inhibit the production of acrolein in the environment and organisms, resulting in environmental pollution and chronic diseases. risk.

Method used

Using ergothionein and its adductive products as acrolein inhibitors, the adduct or crosslinked products formed by capturing acrolein, reduces its active carbonyl compound content and is combined with γ-aminobutyric acid or 5'-guanylate di- Sodium is used for synergistic efficiency and is used as a food additive or health product.

Benefits of technology

Ergothio effectively inhibits the production and reaction of acrolein, improves food safety, prevents chronic diseases caused by acrolein, has stability and high temperature resistance, and can effectively remove acrolein in food processing and organisms, reducing its impact on the human body and Environmental hazards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005013177420000031
    Figure BDA0005013177420000031
  • Figure BDA0005013177420000032
    Figure BDA0005013177420000032
  • Figure BDA0005013177420000071
    Figure BDA0005013177420000071
Patent Text Reader

Abstract

The invention discloses ergothioneine and a combination of the ergothioneine as an acrolein inhibitor, and provides an application of the ergothioneine as the acrolein inhibitor for the first time, and the acrolein inhibitor of the ergothioneine in a preparation environment, food processing or living bodies can rapidly and effectively capture ACR to control the content of ACR, so that the ACR can be quickly and effectively captured by the ergothioneine. The condition that the chitosan is combined with nucleophilic groups in biomacromolecules to form a cross-linked product to hinder normal running of body functions is avoided. The ergothioneine disclosed by the invention can be used as an ACR scavenger to inhibit ACR generated in the environment, in the body and in the food processing process, so that the harm to the environment, food processing and human bodies caused by various harmful adducts or cross-linked products formed by the reaction of the ACR and nucleophilic biological macromolecules is blocked.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to biological inhibitors, and specifically relates to application of ergothioneine and a combination thereof as acrolein inhibitor. Background Art

[0002] Acrolein (ACR) is a highly toxic unsaturated aldehyde that is widely present in the external environment, such as cigarettes, fossil fuels (gasoline or oil), and building fires; secondly, it can also be produced by food processing and endogenous metabolism in the human body. There are large amounts of ACR emissions in automobile exhaust and commercial kitchen fumes. In the brewing process of alcoholic beverages, ACR can be produced by microbial metabolism. For example, the average concentration of ACR in finished liquor can reach 72.3μg / L, and the ACR concentration in whiskey ranges from 700-11100μg / L. As a highly water-soluble α,β-unsaturated aldehyde, ACR can exist in the water environment.

[0003] During food processing, ACR is mainly produced through thermal degradation of carbohydrates and amino acids, fatty acid cleavage, and microbial fermentation metabolism; among them, the ACR content in fried and baked foods is generally high, ranging from 0.001-0.9 mg / kg. In the human body, ACR can be produced endogenously through enzyme-mediated oxidation of polyamines or threonine, through oxidation of unsaturated fatty acids and reactive oxygen species (ROS), and through microbial metabolism in the human intestine.

[0004] As a highly water-soluble α,β-unsaturated aldehyde, ACR can quickly enter physiological tissues. And because of its strong electrophilicity, it has a high reactivity with cellular nucleophilic substances (such as proteins, DNA, and RNA). It reacts with cysteine, histidine, and lysine residues in proteins, affecting the ability of immunoglobulin to recognize antigens, thereby causing autoimmune diseases (Sjögren's syndrome, rheumatoid arthritis); it reacts with guanine bases in DNA to form cyclic addition products, causing DNA damage and then carcinogenicity and mutagenesis; ACR can also cause oxidative stress and lead to neuronal damage.

[0005] Therefore, finding natural, safe and efficient substances to capture ACR to reduce the level of ACR in the environment or in the body and exploring its mechanism is one of the necessary means to prevent environmental pollution and prevent and treat chronic diseases, which has important practical significance and theoretical value.

[0006] The acrolein inhibitors found in the study mainly include polyphenols and flavonoids, including quercetin, catechin, luteolin, genistein, resveratrol, etc. However, the color, smell and solubility of these natural active substances limit their application in food, and their structures are unstable during high-temperature processing, and their long-term effectiveness and subsequent efficacy are not significant.

[0007] Ergothioneine is a white crystal that is easily soluble in water. Its aqueous solution is colorless, has a stable structure, and is not easily decomposed at high temperatures. In 2017, the European Union and the U.S. Food and Drug Administration approved its addition to food as a food supplement. Ergothioneine has a variety of physiologically active functions, such as anti-oxidation, cell protection, anti-inflammation, prevention of cardiovascular disease and diabetes, prevention of neurodegenerative diseases, treatment of mental illness, and anti-aging. At present, research on ergothioneine at home and abroad mainly focuses on antioxidant activity and anti-inflammatory activity, and no research has been found on the inhibition of acrolein by ergothioneine. Summary of the invention

[0008] Purpose of the invention: In view of the problems existing in the prior art, the present invention provides the use of ergothioneine as an acrolein inhibitor, which can effectively inhibit acrolein generated in the environment, food processing and storage, reduce endogenous and exogenous exposure, improve food safety, and simultaneously inhibit the production of acrolein in the environment and organisms, which has very important practical significance and theoretical value for improving environmental protection, food safety, and preventing chronic diseases caused by poor diet.

[0009] Technical solution: In order to achieve the above object, the ergothioneine or its adduct described in the present invention is used as an acrolein inhibitor.

[0010] The invention discloses an application of ergothioneine or an adduct thereof in a preparation environment, food processing or an acrolein inhibitor in a living body.

[0011] Among them, the ergothioneine can inhibit various harmful addition or cross-linking products formed by the reaction of acrolein and nucleophilic biological macromolecules in the preparation environment, food processing or application of acrolein inhibitors in organisms.

[0012] The ergothioneine can capture acrolein to form an addition product, thereby reducing the content of active carbonyl compounds, and is therefore used in acrolein inhibitors in a preparation environment, food processing or in a living body.

[0013] Preferably, the ergothioneine is used in the preparation of an inhibitor for inhibiting the production of acrolein in environmental water and the atmosphere.

[0014] Preferably, the ergothioneine is used in the preparation of an inhibitor for inhibiting the production of acrolein in food or food processing.

[0015] Preferably, the use of ergothioneine in the preparation of an acrolein inhibitor in the human body can prevent the occurrence of chronic diseases in the human body, such as tumors, Alzheimer's disease, aging, atherosclerosis or inflammation caused by the addition or cross-linking of biological nucleophilic macromolecules triggered by acrolein.

[0016] When removing acrolein, the ergothioneine or its adduct can be added to food or health products alone for use, or can be used in combination with other natural or synthetic acrolein scavengers, so as to achieve the purpose of reducing the acrolein content in the environment and human body and reducing the intake of harmful substances by the human body.

[0017] Wherein, the adduct product includes an adduct product of ergothioneine and acrolein, namely EGT-ACR-1, and its structure is shown below:

[0018]

[0019] Wherein, the adduct product includes an adduct product of ergothioneine and acrolein, di-EGT-ACR-2, and its structure is shown below:

[0020]

[0021] The invention discloses an acrolein inhibitor for use in the environment or in food processing, wherein ergothioneine is used as the only component of the inhibitor, or is used as the main component in combination with other substances to form a preparation, and the inhibitor is used in the preparation of the acrolein inhibitor.

[0022] The invention discloses an application of the ergothioneine-containing boletus edulis as an acrolein inhibitor.

[0023] The ergothioneine and gamma-aminobutyric acid or disodium 5'-guanylate described in the present invention are used in combination as acrolein inhibitor.

[0024] The invention discloses an application of the binary combination of ergothioneine and gamma-aminobutyric acid or disodium 5'-guanylate in the preparation of an acrolein inhibitor in a food processing environment or in a living body.

[0025] Preferably, when thioneine and gamma-aminobutyric acid are compounded with a mol ratio of 3:1, when the concentration of thioneine is in the range of 0.3-9.6mmol / L and the concentration of gamma-aminobutyric acid is in the range of 0.1-3.2mmol / L, the two are combined to have a synergistic effect (CI <0.9) of suppressing ACR.

[0026] Preferably, ergothioneine and disodium 5'-guanylate are used in an amount of IC 50 When compounded at a molar ratio of 0.125IC 50 -2IC 50 In the range of ergothioneine concentration of 0.281-4.498mmol / L and 5'-guanylate disodium concentration of 0.520-8.312mmol / L, the combination of the two had a synergistic effect in inhibiting ACR (CI<0.9).

[0027] Ergothioneine is a new application as an acrolein inhibitor, that is, it can quickly and effectively capture ACR to control its content, prevent it from combining with nucleophilic groups (such as amino, sulfhydryl, hydroxyl and imidazole) in biological macromolecules to form cross-linked products, which hinder the normal function of the body. Ergothioneine can be used as a scavenger of ACR, inhibiting ACR produced in the body and during food processing, thereby blocking various harmful addition or cross-linking products formed by the reaction of ACR with nucleophilic biological macromolecules from causing harm to the human body.

[0028] In the present invention, ergothioneine, gamma-aminobutyric acid and disodium 5'-guanylate are all resistant to high temperature, have good water solubility and transparent and colorless solution, and can be directly added to food as food additives or dietary supplements. Therefore, the present invention performs binary combination determination of ergothioneine, gamma-aminobutyric acid and disodium 5'-guanylate with similar properties for the first time to determine the inhibition rate of ACR in a simulation system, calculates the combined action index CI by using CompuSyn software according to the Chou-Talalay calculation method, and finds that the CI values ​​are all less than 0.9, which has an obvious synergistic effect. Then, ergothioneine, gamma-aminobutyric acid and disodium 5'-guanylate are combined as a novel composite acrolein inhibitor and applied to a food system to remove ACR generated in a food processing process, and verifies that using Boletus edulis as a carrier of ergothioneine and gamma-aminobutyric acid, using Straw mushroom as a carrier of disodium 5'-guanylate to compound different types of edible fungi and add them to a baking formula can also play a synergistic effect to remove ACR in the food system.

[0029] The present invention proves for the first time that ergothioneine has the activity of inhibiting ACR, and verifies the mechanism that ergothioneine exerts its inhibitory effect by capturing ACR to form an addition product by synthesizing two adducts of new compounds EGT-ACR-1 and EGT-ACR-2. The present invention combines a variety of non-polyphenol flavonoid ACR inhibitors for the first time to measure their inhibitory effects and successfully proves that the binary combination of ergothioneine and γ-aminobutyric acid and 5'-guanylate disodium has a synergistic effect on the removal of ACR. In addition, for the first time, edible fungi rich in these compounds are used as carriers, mushroom powder is added to cookies and heavy oil cakes, and the formula of biscuits and cakes is improved to increase their nutritional value. At the same time, the ergothioneine, γ-aminobutyric acid and 5'-guanylate disodium contained therein can play a synergistic effect to remove ACR produced during food processing.

[0030] Beneficial effects: Compared with the prior art, the present invention has the following advantages:

[0031] The invention proposes a new application of ergothioneine, that is, for the first time, the content of acrolein can be effectively controlled to avoid the further reaction of acrolein with essential amino acids of the human body or nucleophilic biomacromolecules to form various irreversible harmful addition or cross-linking products.

[0032] Ergothioneine can be used as an inhibitor of acrolein, removes acrolein produced in the environment, in the body, and during food processing, and further blocks the formation of harmful cross-linked products induced by acrolein, preventing the harm caused to the human body. In addition, ergothioneine has been approved by the European Union and the U.S. Food and Drug Administration to be added in food, as an acrolein inhibitor, it has higher safety, and can be used in combination with acrolein scavengers that can be added in other foods to further improve the inhibitory effect. In addition, ergothioneine, as an active ingredient with relatively abundant content in edible fungi, is directly added or eaten in the form of food, and the restriction of exogenous addition can be avoided, so as to better play the role of suppressing acrolein in food processing or in vivo. The present invention first combines a variety of non-polyphenol flavonoid ACR inhibitors to measure their inhibitory effect and successfully proves that ergothioneine and gamma-aminobutyric acid and 5'-guanylate disodium binary combination have a synergistic effect on the removal of ACR. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 It is a reaction path mechanism diagram of ergothioneine and ACR of the present invention;

[0034] Figure 2 It is the mass spectrum of the adduct product of ergothioneine and ACR of the present invention;

[0035] Figure 3 For the present invention under simulated processing conditions, different concentrations of ergothioneine respectively compare the inhibitory activity of acrolein (different capital letters represent the significant difference between different time points, different lowercase letters represent the significant difference between different concentration points, and letters represent statistically p<0.05);

[0036] Figure 4 The present invention is a graph showing the inhibition rate of ACR and Fa-CI curves of ergothioneine, gamma-aminobutyric acid and disodium 5'-guanylate in binary combination under simulated processing conditions (different capital letters represent significant differences between different concentration points, different lowercase letters represent significant differences between different substances, and different letters represent statistically p<0.05);

[0037] Figure 5 The results of the activity determination of the delicious boletus and straw mushroom of the present invention, used alone or in combination, to inhibit ACR in cookies (A) and heavy oil cakes (B) (different capital letters represent significant differences between different addition amounts, different lowercase letters represent significant differences between the experimental group and the control group, and different letters represent statistically p<0.05). DETAILED DESCRIPTION

[0038] The experimental methods described in the examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0039] Example 1

[0040] Purification and structural study of the adduct product of ergothioneine and acrolein

[0041] (1) Experimental materials and instruments

[0042] L-ergothioneine (EGT, chromatographic grade, 95%, BD318101, Shanghai Bi De Pharmaceutical Technology Co., Ltd.); acrolein (ACR, 98% aqueous solution, Shandong Xiya Chemical Industry Co., Ltd.); methanol (analytical grade, Shanghai Sinopharm Chemical Reagent Co., Ltd.); purified water (Hangzhou Wahaha Group Co., Ltd.); ODS filler (ODS-A-HG, 50 μm Fuji Corporation, Japan).

[0043] AVANCE 500MHz nuclear magnetic resonance instrument (Bruker Corporation); Waters Xevo TQ-XS triple quadrupole mass spectrometer (Waters Corporation, USA).

[0044] (2) Experimental procedures

[0045] ① Preparation of the monoaddition product of ergothioneine and acrolein

[0046] Weigh 0.2g thioneine and dissolve in 5mL PBS (pH 7.0, 0.1mol / L), add 5ml of acrolein solution diluted with PBS (pH 7.0, 0.1mol / L), make thioneine and acrolein react 5min at 100 DEG C according to the mol ratio of 1:3.After reaction finishes, add 20μL glacial acetic acid and then ice bath, after ice bath finishes, the reaction solution is rotary evaporated to about 1mL, and the obtained component is glass column chromatography (2.6cm × 30.0cm), and filler is reverse ODS silica gel (ODS-A-HG, 50μm) and adduct is initially separated, and isocratic elution is carried out with 2% methanol-water in volume ratio, and the eluent of the 4th column volume is collected, and the adduct of thioneine and acrolein, EGT-ACR-1 (27mg) is obtained after being spin-dried.

[0047] ② Preparation of the monoaddition product 2 of ergothioneine and acrolein

[0048] Weigh 0.2g thioneine and dissolve in 5mL PBS (pH 7.0, 0.1mol / L), add 5ml of acrolein solution diluted with PBS (pH 7.0, 0.1mol / L), make thioneine and acrolein react 5min at 100 DEG C according to the molar ratio of 1:3. After the reaction is completed, add 20μL glacial acetic acid and then ice bath, after the ice bath is completed, the reaction solution is rotary evaporated to about 1mL, and the resulting component is glass column chromatography (2.6cm × 30.0cm), and the filler is reverse ODS silica gel (ODS-A-HG, 50μm) and the adduct is initially separated, and 2% methanol-water is used for isocratic elution with a volume ratio, and the eluent of the 2nd column volume is collected, and the adduct product two EGT-ACR-2 (18mg) of thioneine and acrolein is obtained after being spin-dried.

[0049] ③Structural identification of EGT-ACR-1 and EGT-ACR-2

[0050] EGT-ACR-1 and EGT-ACR-2 were dissolved in water and diluted to a standard solution of 200 ng / mL. The molecular weight was analyzed by UPLC-MS / MS and 1D-NMR ( 1 H, 13 C), 2D-NMR (HMQC, HMBC) structure analysis.

[0051] Mass spectrometry conditions

[0052] Ion source: Electron Spray Ionization (ESI); Scan mode: Positive ion scan; Detection mode: Multiple Reaction Monitoring (MRM); Capillary voltage: 1.5 kV; Desolvation gas temperature: 500 °C; Desolvation gas flow rate: 1000 L / h; Cone gas flow rate: 150 L / h; Nebulizer flow rate: 7.0 bar; Collision gas flow rate: 0.15 mL / min; Cone voltage: 15 V. Data acquisition and analysis software: MassLynx 4.2.

[0053] Liquid chromatography conditions

[0054] Instrument: Waters Xevo TQ-XS;

[0055] Chromatographic column: ACQUITY UPLC HILIC (2.1×50 mm, id, 1.7 μm);

[0056] Column temperature: 35°C; flow rate: 0.3 mL / min; injection volume: 1 μL;

[0057] Eluent: 0.1% formic acid aqueous solution (mobile phase A); acetonitrile (mobile phase B);

[0058] Elution gradient: 0-1 min, 95% B; 1-3 min, 95-40% B; 3-7 min, 40% B; 7-7.1 min, 40-95% B; 7.1-8 min, 95% B.

[0059] (3) Experimental results

[0060] ①Structural identification of EGT-ACR-1 and EGT-ACR-2

[0061] The prepared EGT-ACR-1 and EGT-ACR-2 were determined by LC-MS / MS. Figure 2 As shown, in positive ion mode, the parent ion mass is m / z 286[M+H] + , compared to the EGT parent ion m / z 230[M+H] + More than 56 (MW ACR 56), and 286[M+H] in MS / MS + The main fragment ion peak of EGT-ACR-1 is m / z 127, which shows that after losing trimethylamine and carboxyl groups, an ACR molecular weight group is lost, indicating that EGT-ACR-1 and EGT-ACR-2 are the addition products of one molecule of ACR and EGT. 1 H and 13 C NMR data are shown in Tables 1 and 2.

[0062] Table 1 Ergothioneine and its ACR product (EGT-ACR-1) 1 H NMR (500 Hz) and 13 C NMR

[0063]

[0064] Table 2 Ergothioneine and its and ACR product (EGT-ACR-2) 1 H NMR (500 Hz) and 13 C NMR

[0065]

[0066] As shown in Table 1, EGT-ACR-1 has similar carbon skeleton with thioneine.First, three newly emerged carbon signals (δC 75.30, δC 29.70 and δC 20.48), and in conjunction with H-16 to C-1, C-4, C-14, the related signal of C-15 in HMBC spectrum, show that C-1, S-6 and N-5 on ACR and imidazole ring form a six-membered ring, in addition, in conjunction with δC 75.30 (C-16) and δH 5.75 (H-16) chemical shift, show that hydroxyl is connected to C-16.Based on these features, the structure of EGT-ACR-1 is finally confirmed, for a new thioneine derivative, and its structural formula is as follows.

[0067]

[0068] As shown in Table 2, EGT-ACR-2 and ergothioneine also have similar carbon skeletons. First, three newly appeared carbon signals (δC 88.29, δC35.95 and δC43.20), combined with the relevant signals of H-16 to C-1, C-4, C-14, and C-15 in the HMBC spectrum, indicate that ACR and C-1, S-6 and N-5 on the imidazole ring form a six-membered ring. In addition, combined with the chemical shifts of δC88.29 (C-14) and δH5.0 (H-14), it is shown that the hydroxyl group is connected to C-14. Based on these characteristics, the structure of EGT-ACR-2 is finally confirmed to be a new ergothioneine derivative, and its structural formula is shown below.

[0069]

[0070] Example 2

[0071] Inhibitory activity of ergothioneine on ACR under simulated processing conditions

[0072] (1) Experimental materials and instruments

[0073] Ergothioneine (EGT, 95%, chromatographic grade, Shanghai BiDe Pharmaceutical Technology Co., Ltd.); acrolein (ACR, 98% aqueous solution, analytical grade); acetonitrile (chromatographic grade, Shanghai Sinopharm Chemical Reagent Co., Ltd.); purified water (Hangzhou Wahaha Group Co., Ltd.); acetic acid, sodium dihydrogen phosphate, and disodium hydrogen phosphate are all analytical grade reagents (Shanghai Sinopharm Chemical Reagent Co., Ltd.); 2,4-dinitrophenylhydrazine hydrochloride (DNPH, 98%, Shanghai TCI Chemical Industry Development Co., Ltd.).

[0074] High performance liquid chromatograph: Waters 2695 (Waters Corporation, USA); QL-861 vortex mixer (Qilin Bell Instrument Manufacturing Co., Ltd., Haimen City, Jiangsu Province).

[0075] (2) Experimental procedures

[0076] ACR solution was prepared with 0.1 mol / L, pH 7.0 PBS to a concentration of 1 mmol / L. 23 mg of thioneine standard product was weighed and added to 10 mL of PBS (0.1 mol / L, pH 7.0) solution to prepare a 10 mmol / L mother liquor. The thioneine mother liquor was then diluted to 1 / 2 / 4 / 6 mmol / L in sequence. In a 10 mL explosion-proof tube, 1 mL of ACR solution (1 mmol / L) and 1 mL of thioneine solution (1 / 2 / 4 / 6 / 10 mmol / L) were added respectively, and 1 mL of PBS (0.1 mol / L, pH 7.0) solution was used instead of thioneine solution as a blank. After vortex mixing, the reaction was carried out at 100 ° C in the dark for 1, 5, 15, 30 and 60 min. After the reaction was completed, 2 μL of acetic acid was immediately added and ice bathed to terminate the reaction. 500 μL of the reaction solution was taken, 300 μL of DNPH solution was added to derivatize at 37 ° C for 2 h, and the ACR clearance rate was calculated. The ACR content was detected by high performance liquid chromatography, and the inhibition rate of thioneine on ACR under simulated processing conditions was calculated. Each sample was made in triplicate.

[0077] The calculation formula of ACR clearance rate is:

[0078]

[0079] HPLC conditions:

[0080] A Waters 2695 high performance liquid chromatograph (Waters, USA) was used for detection, with a Symmetry C18 column (250×4.6 mm, id5 μm), an injection volume of 10 μL, a column temperature of 30°C, a detection wavelength of 372 nm, mobile phase A of acetonitrile, mobile phase B of ultrapure water (containing 0.1% formic acid), a flow rate of 1.0 mL / min, and isocratic elution with 70% mobile phase A for 8.5 min.

[0081] (3) Experimental results

[0082] The reaction mechanism of ergothioneine and ACR is shown in the figure Figure 1 As shown. The activity of ergothioneine in clearing ACR was studied using a simulated food processing model (100℃, pH7.0). First, the elimination of ACR by ergothioneine is time- and dose-dependent. When the addition amount reached 5mmol / L, compared with the blank group, ergothioneine could clear more than 30% of ACR in 1 minute ( Figure 3 ). When the reaction time is extended to 60min, the clearance rate of ACR by ergothioneine can reach nearly 80%. In summary, ergothioneine can effectively remove ACR at high temperature, and the removal effect is good.

[0083] Example 3

[0084] Inhibitory activity of ergothioneine and γ-aminobutyric acid (GABA) / 5'-guanylate disodium (GMP) combined with ACR

[0085] (1) Experimental materials and instruments

[0086] Ergothioneine (EGT, 95%, chromatographic grade, Shanghai BiDe Pharmaceutical Technology Co., Ltd.); γ-aminobutyric acid, disodium 5'-guanylate (98%, chromatographic grade, Shanghai Yuanye Biotechnology Co., Ltd.); acrolein (ACR, 98% aqueous solution, analytical grade); acetonitrile (chromatographic grade, Shanghai Sinopharm Chemical Reagent Co., Ltd.); purified water (Hangzhou Wahaha Group Co., Ltd.); acetic acid, sodium dihydrogen phosphate, and disodium hydrogen phosphate are all analytical grade reagents (Shanghai Sinopharm Chemical Reagent Co., Ltd.); 2,4-dinitrophenylhydrazine hydrochloride (DNPH, 98%, Shanghai TCI Chemical Industry Development Co., Ltd.).

[0087] High performance liquid chromatograph: Waters 2695 (Waters Corporation, USA); QL-861 vortex mixer (Qilin Bell Instrument Manufacturing Co., Ltd., Haimen City, Jiangsu Province).

[0088] (2) Experimental procedures

[0089] ① The inhibitory activity of ergothioneine and γ-aminobutyric acid in a fixed ratio on ACR

[0090] ACR solution was prepared with 0.1mol / L, pH 7.0PBS to a concentration of 1mmol / L; 92mg of ergothioneine standard was weighed, 10mL of PBS (0.1mol / L, pH 7.0) solution was added to prepare a 40mmol / L mother liquor, and then the ergothioneine mother liquor was diluted to 1.2 / 2.4 / 4.8 / 9.6 / 19.2 / 38.4mmol / L in sequence; 20mg of γ-aminobutyric acid standard was weighed, 10mL of PBS (0.1mol / L, pH 7.0) solution was added to prepare a 20mmol / L mother liquor, and then the γ-aminobutyric acid mother liquor was diluted to 0.4 / 0.8 / 1.6 / 3.2 / 6.4 / 12.8mmol / L in sequence. In a 10mL explosion-proof tube, 0.5mL of ergothioneine solution (1.2 / 2.4 / 4.8 / 9.6 / 19.2 / 38.4mmol / L), 0.5mL of γ-aminobutyric acid solution (0.4 / 0.8 / 1.6 / 3.2 / 6.4 / 12.8) and 1mL of ACR solution (1mmol / L) were added respectively. An equal volume of PBS solution was used to replace the corresponding substance solution as a blank. After vortex mixing, the reaction was carried out at 100°C in the dark for 30min. After the reaction was completed, 2μL of acetic acid was immediately added and ice bathed immediately to terminate the reaction. Take 500μL of the reaction solution, add 300μL of DNPH solution and derivatize at 37°C for 2h to calculate the ACR clearance rate. The ACR content was detected by high performance liquid chromatography, and the inhibition rate of ergothioneine on ACR under simulated processing conditions was calculated. Each sample was made in triplicate, and a single ergothioneine or γ-aminobutyric acid of equal concentration was used as a control. CompuSyn software was used to calculate the combined effect index CI according to the Chou-Talalay calculation method. When CI < 0.9, the two showed a synergistic effect, when 0.9 ≤ CI ≤ 1.1, the two showed an additive effect, and when CI > 1.1, the two showed an antagonistic effect. The inhibitory effect of the combined effect of the two on ACR was then evaluated based on the results.

[0091] ②Ergothioneine and 5'-guanylate disodium according to IC 50 Inhibitory activity of the ratio of binary combination on ACR

[0092] ACR solution was prepared with 0.1mol / L, pH 7.0PBS to a concentration of 1mmol / L. 46mg of thioneine standard product was weighed, 10mL of PBS (0.1mol / L, pH 7.0) solution was added to prepare a 20mmol / L mother liquor, and then the thioneine mother liquor was diluted to 1.125 / 2.249 / 4.498 / 8.996 / 17.992 / 35.987mmol / L in sequence; 164mg of 5'-disodium guanylate standard product was weighed, 10mL of PBS (0.1mol / L, pH 7.0) solution was added to prepare a 40mmol / L mother liquor, and then the 5'-disodium guanylate mother liquor was diluted to 2.078 / 4.156 / 8.312 / 16.624 / 33.248mmol / L in sequence. In a 10mL explosion-proof tube, 0.5mL of thioneine solution (1.125 / 2.249 / 4.498 / 8.996 / 17.992mmol / L), 0.5mL of 5'-guanylate disodium solution (2.078 / 4.156 / 8.312 / 16.624 / 33.248mmol / L) and 1mL of ACR solution (1mmol / L) were added respectively. 1mL of PBS solution was used instead of thioneine solution as a blank. After vortex mixing, the reaction was carried out at 100℃ in the dark for 30min. After the reaction was completed, 500μL of the reaction solution was taken, and 300μL of DNPH solution was added to derivatize at 37℃ for 2h to calculate the ACR clearance rate. The ACR content was detected by high performance liquid chromatography, and the inhibition rate of thioneine on ACR under simulated processing conditions was calculated. Three parallel groups were made for each sample. CompuSyn software was used to calculate the combined effect index CI according to the Chou-Talalay calculation method to analyze and evaluate the inhibitory effect of the combined effect of the two on ACR.

[0093] The calculation formula of ACR clearance rate is:

[0094]

[0095] HPLC conditions:

[0096] A Waters 2695 high performance liquid chromatograph (Waters, USA) was used for detection, with a Symmetry C18 column (250×4.6 mm, id5 μm), an injection volume of 10 μL, a column temperature of 30°C, a detection wavelength of 372 nm, mobile phase A of acetonitrile, mobile phase B of ultrapure water (containing 0.1% formic acid), a flow rate of 1.0 mL / min, and isocratic elution with 70% mobile phase A for 8.5 min.

[0097] (3) Experimental results

[0098] The Chou-Talalay rule was used to evaluate the scavenging effect of ergothioneine, γ-aminobutyric acid and disodium 5'-guanylate on ACR, and the combined action index (CI value) of the two combinations was calculated by CompuSyn 2.0 software, where CI < 0.9 was synergistic, 0.9 ≤ CI ≤ 1.1 was additive, and CI > 1.1 was antagonistic.

[0099] like Figure 4 As shown in Figures A and 4B, for ACR, when ergothioneine and γ-aminobutyric acid are compounded in a molar ratio of 3:1, when the concentration of ergothioneine is in the range of 0.3-9.6mmol / L and the concentration of γ-aminobutyric acid is in the range of 0.1-3.2mmol / L, both have a synergistic effect of inhibiting ACR (CI<0.9), and the synergistic inhibition rate can reach up to 76%, with excellent inhibitory activity, and more significant than the single use of any inhibitor.

[0100] like Figure 4 As shown in C and 4D, ergothioneine and 5'-guanylate disodium were measured at IC 50 When compounded at a molar ratio of 0.125IC 50 -2 IC 50 Within the range (ergothioneine is 0.281-4.498mmol / L, 5'-guanylate disodium is 0.520-8.312mmol / L), both have the effect of synergistically inhibiting ACR (CI<0.9), and the synergistic inhibition rate can reach up to 88%, which has a good ACR effect.

[0101] The above experiments further prove that ergothioneine of the present invention itself can not only have a very good inhibitory effect as an acrolein inhibitor, but also can be used in conjunction with the binary system of gamma-aminobutyric acid / 5'-disodium guanylate, which can more significantly inhibit acrolein in a short time, and has obvious synergistic effect.

[0102] Example 4

[0103] Study on the scavenging effect of Boletus edulis on acrolein produced during the baking process of heavy oil cakes and cookies

[0104] (1) Experimental materials and instruments

[0105] Delicious porcini (Shanyexiang Farm Store, Kunming, Yunnan), straw mushrooms (Guan'er flagship store, Gutian County Runkang Food Co., Ltd.), ergothioneine (EGT, 95%, chromatographically pure, Shanghai Bid Pharmaceutical Technology Co., Ltd.); γ-aminobutyric acid, 5'-guanylate disodium (98%, chromatographically pure, Shanghai Yuanye Biotechnology Co., Ltd.); low-gluten flour (Shanghai Yihai Kerry International Trade Co., Ltd.); salt, white sugar, butter, baking powder and eggs (Hongli Ajia Supermarket, Suqian City, Jiangsu Province).

[0106] Waters 2695 high performance liquid chromatograph (Waters Corporation, USA); ZQTY-70 tabletop shaking incubator (Shanghai Zhichu Instrument Co., Ltd.); QL-861 vortex mixer (Qilin Bell Instrument Manufacturing Co., Ltd., Haimen City, Jiangsu Province); KQ-300B ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); water bath (Jintan Digital Display Constant Temperature Water Bath); CRTF32K oven (Changdi Electric Appliance Co., Ltd.).

[0107] (2) Experimental procedures

[0108] ① Preparation of heavy oil cakes and cookies

[0109] This example uses Boletus edulis and Volvariella volvacea as examples to demonstrate the combined effect of ergothioneine, γ-aminobutyric acid, and disodium 5'-guanylate.

[0110] Preparation of heavy oil cake: First, heat 30.0g butter until it softens slightly, add 30g low-gluten flour, add 30.0g white sugar, and stir them with a handheld electric mixer until they turn slightly white. Add 30.0g fresh whole egg liquid in batches, stir evenly, then add 30.0g low-gluten flour, 0.3g salt and 0.6g baking powder, and then stir with a handheld electric mixer for 4 minutes to make the cake batter required for heavy oil cake. Transfer the cake batter to the mold on the baking tray, put it in the preheated oven, and bake it at 175℃ for 45 minutes with both upper and lower fires. After cooling, crush the heavy oil cake and freeze it in a -80℃ refrigerator for later use. All samples were made in triplicate.

[0111] Preparation of cookies: Weigh 32g butter and 25g sucrose, mix them and stir them in a blender at medium speed until fluffy, then add 12.5g egg liquid, stir evenly, add 50g sifted low-gluten flour and 0.75g baking soda, and stir evenly in a blender at low speed. Use a mold to make the cookie dough into a 5cm diameter and 2mm thickness embryo, then place it in an oven, bake at 180℃ on the upper fire and 170℃ on the lower fire for 15min. After the end, cool the sample to room temperature, crush it and store it at -20℃ for testing.

[0112] a. Prepare heavy oil cakes and cookies respectively: ① without adding delicious porcini powder or ergothioneine and γ-aminobutyric acid as a blank group; ② adding 4 / 6 / 8% (calculated by flour mass ratio) delicious porcini powder to egg liquid as an experimental group; ③ adding 38.4mg, 57.6mg, 76.8mg pure ergothioneine and 5.2mg, 7.8mg, 10.4mg pure γ-aminobutyric acid to egg liquid as a control group, to explore the activity of ergothioneine and γ-aminobutyric acid in combination to inhibit acrolein in the baking system.

[0113] b. The addition amount of fixed mushroom powder is 10% (calculated by flour mass ratio), of which the addition amount of delicious boletus powder is 2% (corresponding to 19.2 mg of pure ergothioneine, at which time γ-aminobutyric acid can be ignored), and the addition amount of straw mushroom powder is 8% (corresponding to 33.3 mg of pure 5'-guanylate disodium), and the following are respectively prepared: ① no addition of mushroom powder as a blank group ② adding two kinds of mushroom powder to the egg liquid as an experimental group ③ adding ergothioneine and 5'-guanylate disodium pure products to the egg liquid as a control group of cookies and heavy oil cakes, to explore the activity of ergothioneine and 5'-guanylate disodium in combination in the baking system to inhibit acrolein.

[0114] ②Study on the activity of ergothioneine in scavenging acrolein in baking system

[0115] Weigh 0.5 g of crushed heavy oil cake / cookie sample and place it in a 50 mL centrifuge tube, add 5 mL of a mixture containing methanol and PBS (pH 7.0, 0.1 mol / L) solution in a ratio of 1:1 (50:50, v / v), vortex mix for 3 min, ultrasonically extract at 40 °C for 60 min, then centrifuge at 10000 r / min, 4 °C for 15 min, then take 500 μL of sample solution and add 300 μL of DNPH solution, vortex mix and derivatize at 37 °C for 2 h, after the reaction is completed, add 3 mL of dichloromethane solution and vortex for 30 s, then ultrasonically extract for 15 min under ice bath conditions, after the extraction is completed, centrifuge at 10000 r / min, 4 °C for 10 min, take the dichloromethane layer, and then repeat the extraction twice, finally mix the dichloromethane layers, blow dry with a nitrogen blower, and use 200 μL The mixture was reconstituted with 70% acetonitrile aqueous solution and the ACR content in the heavy oil cake / cookies was determined by HPLC according to the method in Example 2, with six replicates for each sample.

[0116] (3) Experimental results

[0117] like Figure 5 As shown in the figure, adding different doses of Boletus edulis to the scavenging activity of ACR in heavy oil cakes / cookies showed a dose-effect relationship. When the addition amount of Boletus edulis was 8%, the inhibition rate of ACR could reach about 60%; when pure ergothioneine and γ-aminobutyric acid were added, the inhibition rate of ACR in heavy oil cakes / cookies was about 5%-10% higher than that of the group adding Boletus edulis. This may be because EGT and GABA in Boletus edulis were not completely dissolved in the biscuit and cake system, or there were interferences from other components in Boletus edulis. In summary, ergothioneine and γ-aminobutyric acid contained in Boletus edulis can also play a synergistic role in the actual food processing system, and have the ability to efficiently remove ACR.

[0118] When 2% of Boletus edulis and 8% of Volvariella volvacea were added to heavy oil cakes and cookies, the inhibition rate of ACR reached about 70%. The inhibition rate of ACR in the control group that only added pure ergothioneine and 5'-disodium guanylate could reach 75%, which was slightly higher than that of the experimental group. This may be because the EGT and GMP in Boletus edulis and Volvariella volvacea were not completely dissolved in the biscuit and cake system, or there were interferences from other components in Boletus edulis and Volvariella volvacea. This proves that the ergothioneine in Boletus edulis and the 5'-disodium guanylate in Volvariella volvacea can also play a synergistic role in the actual food processing system, thereby producing a good ACR inhibition effect.

Claims

1. Use of ergothioneine or its adducts as acrolein inhibitor.

2. Application of ergothioneine or its adducts in the preparation environment, food processing or as acrolein inhibitor in organisms.

3. The use according to claim 1 or 2, characterized in that: The ergothioneine can inhibit various harmful addition or cross-linking products formed by the reaction of acrolein and nucleophilic biological macromolecules and is used in the preparation environment, food processing or acrolein inhibitor in organisms.

4. The use according to claim 1 or 2, characterized in that: The ergothioneine can capture acrolein to form an addition product, thereby reducing the content of active carbonyl compounds, and is therefore used in acrolein inhibitors in a preparation environment, food processing or in a living body.

5. The use according to claim 4, characterized in that: The adduct product includes an adduct product of ergothioneine and acrolein, namely EGT-ACR-1, whose structure is shown below:

6. The use according to claim 4, characterized in that: The adduct comprises an adduct of ergothioneine and acrolein, di-EGT-ACR-2, the structure of which is shown below:

7. An acrolein inhibitor in the environment and in food processing, characterized in that The inhibitor uses ergothioneine as the only component in the inhibitor, or is used as the main component in combination with other substances to form a preparation, and is used in the preparation of acrolein inhibitor.

8. Application of ergothioneine-containing Boletus edulis as an acrolein inhibitor.

9. Ergothioneine and γ-aminobutyric acid or disodium 5'-guanylate are used in combination as acrolein inhibitors.

10. Application of ergothioneine and γ-aminobutyric acid or disodium 5'-guanylate in combination as acrolein inhibitor in the preparation environment, food processing or in organisms.